NASDAQ:ANAC - Anacor Pharmaceuticals Stock Price, Price Target & More

$99.06 -0.14 (-0.14 %)

(As of 04/26/2018 04:00 PM ET)

Previous Close$99.20

Today's Range$99.06 - $99.06

52-Week Range$52.00 - $156.93

Volume300 shs

Average Volume1.81 million shs

Market Capitalization$4.50 billion

P/E RatioN/A

Dividend YieldN/A

Beta1.53

About Anacor Pharmaceuticals (NASDAQ:ANAC)

Anacor Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on discovering, developing and commercializing small-molecule therapeutics derived from its boron chemistry platform. Its lead product development candidate is crisaborole topical ointment, approximately 2%, a non-steroidal topical anti-inflammatory phosphodiesterase-4 (PDE-4) inhibitor in development for the treatment of mild-to-moderate atopic dermatitis and psoriasis. Its product, KERYDIN (tavaborole) topical solution, approximately 5%, is an oxaborole antifungal approved by the United States Food and Drug Administration (FDA) for the topical treatment of onychomycosis of the toenails. It also has a pipeline of other internally discovered topical and systemic boron-based compounds in early-stages of research and development, which include AN3365. Its compound, AN5568 (SCYX-7158), is licensed to Drugs for Neglected Diseases initiative (DNDi) for the treatment of human African trypanosomiasis.

Receive ANAC News and Ratings via Email

Sign-up to receive the latest news and ratings for ANAC and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry N/A

Sub-IndustryBiotechnology

SectorN/A

SymbolNASDAQ:ANAC

CUSIP03242010

Webwww.anacor.com

Phone+1-650-5437500

Debt

Debt-to-Equity RatioN/A

Current RatioN/A

Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual SalesN/A

Price / SalesN/A

Cash FlowN/A

Price / CashN/A

Book ValueN/A

Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A

Net IncomeN/A

Net Margins-92.08%

Return on Equity-133.71%

Return on Assets-38.09%

Miscellaneous

EmployeesN/A

Outstanding Shares44,860,000

How to Become a New Pot Stock Millionaire

Anacor Pharmaceuticals (NASDAQ:ANAC) Frequently Asked Questions

What is Anacor Pharmaceuticals' stock symbol?

Anacor Pharmaceuticals trades on the NASDAQ under the ticker symbol "ANAC."

How were Anacor Pharmaceuticals' earnings last quarter?

Anacor Pharmaceuticals Inc (NASDAQ:ANAC) posted its quarterly earnings data on Tuesday, May, 10th. The biopharmaceutical company reported ($0.36) EPS for the quarter, missing the Zacks' consensus estimate of ($0.35) by $0.01. The biopharmaceutical company earned $17.54 million during the quarter, compared to the consensus estimate of $19.53 million. Anacor Pharmaceuticals had a negative return on equity of 133.71% and a negative net margin of 92.08%. The firm's quarterly revenue was up 14.9% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.30) EPS. View Anacor Pharmaceuticals' Earnings History.

Has Anacor Pharmaceuticals been receiving favorable news coverage?

Media coverage about ANAC stock has been trending somewhat positive this week, according to Accern. The research group scores the sentiment of press coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Anacor Pharmaceuticals earned a daily sentiment score of 0.11 on Accern's scale. They also assigned media headlines about the biopharmaceutical company an impact score of 46.42 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company's share price in the near future.

How do I buy shares of Anacor Pharmaceuticals?

Shares of ANAC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Anacor Pharmaceuticals' stock price today?

One share of ANAC stock can currently be purchased for approximately $99.06.

How big of a company is Anacor Pharmaceuticals?

Anacor Pharmaceuticals has a market capitalization of $4.50 billion.

How can I contact Anacor Pharmaceuticals?

Anacor Pharmaceuticals' mailing address is 1020 E Meadow Cir, PALO ALTO, CA 94303-4230, United States. The biopharmaceutical company can be reached via phone at +1-650-5437500.

MarketBeat Community Rating for Anacor Pharmaceuticals (ANAC)

Community Ranking:		3.5 out of 5 ( )
Outperform Votes:		249 (Vote Outperform)
Underperform Votes:		111 (Vote Underperform)
Total Votes:		360

MarketBeat's community ratings are surveys of what our community members think about Anacor Pharmaceuticals and other stocks. Vote "Outperform" if you believe ANAC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ANAC will underperform the S&P 500 over the long term. You may vote once every thirty days.

Anacor Pharmaceuticals (NASDAQ:ANAC) Price Target and Consensus Rating

(How are Consensus Ratings Calculated?)

	Today	30 Days Ago	90 Days Ago	180 Days Ago
Consensus Rating:	N/A	N/A	N/A	N/A
Consensus Rating Score:	N/A	N/A	N/A	N/A
Ratings Breakdown:	0 Sell Rating(s) 0 Hold Rating(s) 0 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 0 Hold Rating(s) 0 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 0 Hold Rating(s) 0 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 0 Hold Rating(s) 0 Buy Rating(s) 0 Strong Buy Rating(s)
Consensus Price Target:	N/A	N/A	N/A	N/A
Price Target Upside:	N/A	N/A	N/A	N/A

Anacor Pharmaceuticals (NASDAQ:ANAC) Consensus Price Target History

Price Target History for Anacor Pharmaceuticals (NASDAQ:ANAC)

Anacor Pharmaceuticals (NASDAQ:ANAC) Analyst Ratings History

Show:

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
5/18/2016	Mizuho	Downgrade	Buy -> Neutral	$98.00 -> $99.25	N/A
5/16/2016	Jefferies Group	Reiterated Rating	Buy		N/A
5/16/2016	Wedbush	Downgrade	Outperform -> Neutral	$148.00 -> $99.25	N/A
5/10/2016	Cowen	Reiterated Rating	Buy		N/A

(Data available from 4/26/2016 forward)

Anacor Pharmaceuticals (NASDAQ:ANAC) Earnings History and Estimates Chart

Earnings by Quarter for Anacor Pharmaceuticals (NASDAQ:ANAC)

Anacor Pharmaceuticals (NASDAQ ANAC) Earnings History by Quarter

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
5/10/2016	Q116	($0.35)	($0.36)	$19.53 million	$17.54 million	View	Listen
2/29/2016	Q415	($0.30)	($0.43)	$27.93 million	$21.20 million	View	Listen
11/3/2015	Q315	($0.23)	($0.37)	$25.60 million	$24.60 million	View	Listen
8/6/2015	Q215	($0.32)	($0.30)	$18.55 million	$21.30 million	View	N/A
5/6/2015	Q115	($0.47)	($0.30)	$9.20 million	$15.26 million	View	N/A
3/12/2015	Q414	($0.59)	($0.21)	$4.74 million	$9.60 million	View	N/A
11/6/2014	Q314	($0.65)	($0.74)	$3.67 million	$3.96 million	View	N/A
8/7/2014	Q214	($0.63)	($0.58)	$3.03 million	$2.90 million	View	N/A
5/7/2014	Q114	($0.39)	($0.51)	$2.82 million	$4.15 million	View	N/A
3/13/2014	Q413	$3.01	$3.01	$2.85 million	$8.50 million	View	N/A
11/7/2013	Q3 2013	($0.36)	($0.41)	$2.85 million	$3.61 million	View	N/A
8/8/2013	Q2 2013	($0.39)	($0.36)	$2.60 million	$3.40 million	View	N/A
5/9/2013	Q1 2013	($0.39)	($0.42)	$2.57 million	$1.7080 billion	View	N/A
3/14/2013	Q4 2012	($0.45)	($0.36)	$3.25 million	$3.28 million	View	N/A
11/7/2012	Q312	($0.45)	($0.46)	$3.18 million	$2.47 million	View	N/A
8/9/2012		($0.45)	($0.47)			View	N/A
5/10/2012		($0.44)	($0.48)			View	N/A
3/13/2012		($0.35)	($0.52)			View	N/A
11/10/2011		($0.41)	($0.16)			View	N/A
8/11/2011		($0.45)	($0.54)			View	N/A
5/5/2011		($0.31)	($0.49)			View	N/A
3/10/2011	Q4 2010	($0.47)	($0.73)			View	N/A

(Earnings results data provided by Zacks Investment Research)

Anacor Pharmaceuticals (NASDAQ:ANAC) Dividend History by Quarter

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date

(Data available from 1/1/2013 forward)

Anacor Pharmaceuticals (NASDAQ ANAC) Insider Trading and Institutional Ownership History

Insider Trading History for Anacor Pharmaceuticals (NASDAQ:ANAC)

Anacor Pharmaceuticals (NASDAQ ANAC) Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
6/1/2016	Graeme Bell	CFO	Sell	751	$99.28	$74,559.28	10,255
5/23/2016	Keith R Leonard	Director	Sell	9,000	$99.70	$897,300.00	9,794
5/16/2016	Anders D Hove	Director	Sell	353,881	$99.59	$35,243,008.79
4/29/2016	Ryan T Sullivan	EVP	Sell	3,125	$66.33	$207,281.25	30,132
4/8/2016	Anders D Hove	Director	Sell	229,301	$71.10	$16,303,301.10
3/22/2016	Paul L Berns	CEO	Sell	37,500	$60.31	$2,261,625.00	258,111
1/19/2016	Vincent P. Ippolito	EVP	Sell	20,000	$95.41	$1,908,200.00	70,985
1/15/2016	Lee Zane	SVP	Sell	1,466	$89.57	$131,309.62	27,281
1/4/2016	Paul L. Berns	CEO	Sell	2,533	$112.35	$284,582.55	252,227
1/4/2016	Ryan T. Sullivan	VP	Sell	733	$111.78	$81,934.74	27,007
1/4/2016	Vincent P. Ippolito	EVP	Sell	855	$112.28	$95,999.40	70,985
12/11/2015	Paul L. Berns	CEO	Sell	20,000	$117.26	$2,345,200.00	254,760
12/10/2015	Ryan T. Sullivan	VP	Sell	10,000	$110.41	$1,104,100.00	27,740
9/15/2015	Lee Zane	SVP	Sell	14,000	$139.84	$1,957,760.00	28,744
9/15/2015	Paul L. Berns	CEO	Sell	20,000	$139.83	$2,796,600.00	254,760
8/13/2015	Paul L Berns	CEO	Sell	20,000	$138.69	$2,773,800.00
6/15/2015	Lee Zane	SVP	Sell	12,000	$69.05	$828,600.00
5/15/2015	Jacob J Plattner	VP	Sell	8,920	$63.73	$568,471.60
5/14/2015	Carmen R Rodriguez	VP	Sell	61,942	$62.73	$3,885,621.66
4/29/2015	Ryan T Sullivan	VP	Sell	3,125	$53.61	$167,531.25
4/27/2015	Paul L Berns	CEO	Sell	50,000	$63.64	$3,182,000.00
4/15/2015	Jacob J Plattner	VP	Sell	8,920	$62.81	$560,265.20
3/23/2015	Geoffrey M Parker	CFO	Buy	3,000	$52.43	$157,290.00
3/16/2015	Jacob J Plattner	VP	Sell	8,920	$55.60	$495,952.00
3/16/2015	Lee Zane	SVP	Sell	12,000	$56.44	$677,280.00
3/4/2015	Sanjay Chanda	SVP	Sell	5,000	$45.00	$225,000.00
3/3/2015	Vincent P Ippolito	EVP	Sell	9,000	$43.88	$394,920.00
3/2/2015	Jacob J Plattner	VP	Sell	6,875	$44.02	$302,637.50
3/2/2015	Kirk R Maples	SVP	Sell	600	$43.95	$26,370.00
1/2/2015	Jacob J Plattner	VP	Sell	6,875	$32.09	$220,618.75
12/26/2014	Paul L Berns	CEO	Sell	25,000	$30.82	$770,500.00
12/12/2014	Lucy Shapiro	Director	Sell	289,685	$35.11	$10,170,840.35
12/11/2014	Lee Zane	SVP	Sell	4,900	$36.09	$176,841.00
12/9/2014	Kirk R Maples	SVP	Sell	60,000	$36.52	$2,191,200.00
12/1/2014	Jacob J Plattner	VP	Sell	6,875	$33.34	$229,212.50
12/1/2014	Kirk R Maples	SVP	Sell	600	$33.38	$20,028.00
11/26/2014	Sanjay Chanda	SVP	Sell	5,000	$35.00	$175,000.00
11/3/2014	Jacob J Plattner	VP	Sell	6,875	$29.32	$201,575.00
10/1/2014	Jacob J Plattner	VP	Sell	6,875	$24.47	$168,231.25
9/26/2014	Anders D Hove	Director	Sell	20,000	$25.00	$500,000.00
9/19/2014	Anders D Hove	Director	Sell	740,000	$24.87	$18,403,800.00
9/16/2014	Anders D Hove	Director	Sell	90,000	$24.99	$2,249,100.00
9/10/2014	Sanjay Chanda	SVP	Sell	10,000	$24.25	$242,500.00
9/8/2014	Geoffrey M Parker	CFO	Buy	6,590	$21.82	$143,793.80
8/27/2014	Mark Leschly	Director	Sell	13,067	$22.50	$294,007.50
5/20/2014	Kirk Maples	SVP	Sell	1,500	$14.15	$21,225.00	1,620
4/21/2014	Kirk Maples	SVP	Sell	1,500	$15.60	$23,400.00	3,120
3/24/2014	Geoffrey Parker	CFO	Buy	5,000	$20.11	$100,550.00	86,000
3/21/2014	Lucy Shapiro	Director	Sell	80,000	$21.14	$1,691,200.00	36,248
3/20/2014	Kirk Maples	SVP	Sell	3,000	$22.39	$67,170.00	4,620
3/18/2014	Geoffrey Parker	CFO	Buy	2,410	$22.60	$54,466.00	86,000
3/5/2014	David Perry	CEO	Sell	65,000	$20.22	$1,314,300.00	361,306
2/20/2014	Kirk Maples	SVP	Sell	3,000	$19.33	$57,990.00	7,620
2/5/2014	David Perry	CEO	Sell	15,000	$17.00	$255,000.00	426,306
1/21/2014	Kirk Maples	SVP	Sell	3,000	$20.27	$60,810.00	9,620
1/9/2014	David Perry	CEO	Sell	65,000	$16.32	$1,060,800.00	441,306
12/9/2013	David Perry	CEO	Sell	40,328	$16.23	$654,523.44	506,306
11/26/2013	Geoffrey Parker	CFO	Buy	10,000	$13.40	$134,000.00	85,000
11/25/2013	Geoffrey Parker	CFO	Buy	10,000	$12.85	$128,500.00	85,000
8/14/2013	Kirk Maples	SVP	Sell	1,052	$9.71	$10,214.92
8/13/2013	Geoffrey Parker	CFO	Buy	50,000	$8.34	$417,000.00	5,000
6/19/2013	Geoffrey M Parker	CFO	Buy	23,046	$5.20	$119,839.20
6/18/2013	Geoffrey M Parker	CFO	Buy	20,000	$5.22	$104,400.00
6/14/2013	Kirk R Maples	SVP	Sell	5,600	$5.39	$30,184.00
11/26/2012	Kirk R Maples	SVP	Sell	3,000	$5.22	$15,660.00
11/1/2012	Kirk R Maples	SVP	Sell	3,000	$5.81	$17,430.00
10/5/2012	Lucy Shapiro	Director	Sell	30,000	$6.67	$200,100.00
8/22/2012	Geoffrey M Parker	CFO	Buy	5,000	$6.19	$30,950.00

(Data available from 1/1/2013 forward)

Anacor Pharmaceuticals (NASDAQ ANAC) News Headlines

Source:

Date	Headline
	Dupixent Could Substantially Drive Regeneron’s Growth finance.yahoo.com - March 23 at 5:14 PM
	Reviewing Anacor Pharmaceuticals (ANAC) & Sorrento Tech (ROKA) www.americanbankingnews.com - March 21 at 1:08 AM
	Head to Head Analysis: Anacor Pharmaceuticals (ANAC) and Qiagen (QGEN) www.americanbankingnews.com - March 20 at 3:22 PM
	Head to Head Survey: Albany Molecular Research (AMRI) and Anacor Pharmaceuticals (ANAC) www.americanbankingnews.com - March 18 at 7:26 PM
	Novavax (NVAX) versus Anacor Pharmaceuticals (ANAC) Head to Head Comparison www.americanbankingnews.com - March 4 at 9:15 PM
	Intercept Pharmaceuticals (ICPT) CEO Mark Pruzanski on Q4 2017 Results - Earnings Call Transcript seekingalpha.com - February 14 at 5:13 PM
	Critical Survey: Anacor Pharmaceuticals (ANAC) & The Competition www.americanbankingnews.com - December 20 at 9:28 PM
	Repros Therapeutics (RPRX) & Anacor Pharmaceuticals (ANAC) Head-To-Head Analysis www.americanbankingnews.com - December 6 at 8:02 AM
	Reviewing Genomic Health (GHDX) & Anacor Pharmaceuticals (ANAC) www.americanbankingnews.com - November 28 at 9:08 PM
	Anacor Pharmaceuticals (ANAC) and Its Rivals Critical Comparison www.americanbankingnews.com - November 25 at 3:20 PM
	Comparing Anacor Pharmaceuticals (ANAC) and The Competition www.americanbankingnews.com - November 22 at 8:05 AM
	Upcoming Earnings: Pfizer Reports Tomorrow As Management Explores Alternatives For Consumer Healthcare finance.yahoo.com - October 30 at 4:49 PM
	Better Buy: Pfizer Inc. vs. Bristol-Myers Squibb -- The Motley Fool - Motley Fool www.fool.com - September 17 at 3:41 PM
	Better Buy: Pfizer Inc. vs. Bristol-Myers Squibb -- The Motley Fool - Motley Fool www.fool.com - September 17 at 3:40 PM
	Suneva Medical Expands their Prestigious Board of Directors with the Appointment of Vince Ippolito www.prnewswire.com - August 28 at 3:58 PM
	Here's How Much $10,000 Invested in Pfizer in 1977 Is Worth Now ... - Motley Fool www.fool.com - August 21 at 9:00 PM
	Shire chief financial officer joins Boston ag-tech startup www.bizjournals.com - August 21 at 4:00 PM
	Pfizer Investors Keep Eyes on Pipeline as Viagra, Lyrica Approach Patent Cliff - TheStreet.com www.thestreet.com - July 31 at 3:57 PM
	Pharma Giant Pfizer Reports Q2 Earnings Tomorrow Morning - Seeking Alpha seekingalpha.com - July 31 at 3:57 PM
	These 2 Pharma Giants May Be on Pfizer's M&A Radar Right Now ... - Motley Fool www.fool.com - July 26 at 4:23 PM
	The Stock Market Is Very Expensive: 5 Safe Blue Chips to Buy Now 247wallst.com - July 24 at 1:15 PM
	3 Dividend Stocks That Are Minting Money -- The Motley Fool - Motley Fool www.fool.com - July 13 at 9:46 PM
	North America Will Continue to be the Most Lucrative Market for ... - PR Newswire (press release) www.prnewswire.com - June 27 at 3:37 PM
	3 Stocks to Help You Build Retirement Wealth -- The Motley Fool - Motley Fool www.fool.com - June 25 at 8:43 PM
	Top 3 Emerging Trends Impacting the Global Anti-Inflammatory ... - Business Wire (press release) www.businesswire.com - June 23 at 9:05 PM
	Spherix Inc. Announces Definitive Terms Reached to Acquire ... - PR Newswire (press release) www.prnewswire.com - June 20 at 4:09 PM
	Pfizer unloading space after $14 billion Medivation deal www.bizjournals.com - May 8 at 11:01 AM
	PFIZER REPORTS FIRST-QUARTER 2017 RESULTS www.businesswire.com - May 2 at 7:52 AM
	Biotech M&A Plunges as Trump Attacks Drug Companies - Investopedia www.investopedia.com - April 24 at 3:34 PM
	Canada's Cannabis Boom Creating a $30 Billion Investment Opportunity - Baystreet.ca www.baystreet.ca - April 20 at 3:36 PM
	5 Stocks to Watch as Canada Gets Hooked on Cannabis - PR Newswire (press release) www.prnewswire.com - April 18 at 8:34 AM
	1 Top Stock in Big Pharma -- The Motley Fool - Motley Fool www.fool.com - March 27 at 7:32 AM
	1 Top Stock in Big Pharma - Motley Fool www.fool.com - March 25 at 11:40 AM
	Buy Pfizer: Income Play With Good Growth Coming seekingalpha.com - March 17 at 3:38 PM
	These Were the 10 Biggest Pharmaceutical Deals of 2016 - Fortune fortune.com - February 24 at 3:44 PM
	Better Buy: Pfizer Inc. vs. Merck & Co. Inc. -- The Motley Fool - Motley Fool www.fool.com - February 21 at 3:48 PM
	4 High-Yield Dividend Stocks You Don't Have to Babysit - Motley Fool www.fool.com - February 16 at 8:27 AM
	5 Things Pfizer's Management Wants You to Know - Motley Fool www.fool.com - February 1 at 3:37 PM
	Top 5 Vendors in the Global Atopic Dermatitis Drugs Market from 2017 to 2021: Technavio - Business Wire (press release) www.businesswire.com - February 1 at 3:37 PM
	Are Pfizer's Acquisitions Holding Back Its Bottom Line? - 24/7 Wall St. 247wallst.com - January 31 at 3:42 PM
	3 Reasons to Buy Pfizer Stock and Never Sell -- The Motley Fool - Motley Fool www.fool.com - January 31 at 2:25 AM
	All Eyes on Growth Plans as Pfizer Gears Up for Fourth Quarter ... - TheStreet.com www.thestreet.com - January 31 at 2:25 AM
	A Mixed Bag of Earnings Ahead: Eli Lilly, Pfizer, Exxon Mobil, And Under Armour - Benzinga www.benzinga.com - January 30 at 3:54 PM
	Drugmakers Plan Huge Deals in 2017 -- and Banks Will Collect Big Fees - TheStreet.com www.thestreet.com - January 24 at 8:28 PM